Wegovy (semaglutide) is an FDA-approved weight management treatment taken once weekly as an oral tablet. This guide explains Wegovy pill milligrams in plain terms: available strengths, how dosing increases over time, and practical steps for each new level. It covers what to expect from starting Wegovy to reaching the maintenance dose, how titration works, and how this oral option compares with other semaglutide products. The information here is evergreen and meant to support safe, informed conversations with your healthcare provider.
What Wegovy is and how it works
Wegovy is a once-weekly oral medication containing semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA) used for chronic weight management in adults with obesity or overweight with at least one weight-related condition. It acts on receptors in the brain involved in appetite regulation and gastric emptying. It is not insulin, a steroid, or a stimulant. Results build over weeks and months, and treatment is most effective alongside sustainable diet and activity changes. Because it is a long-acting molecule formulated for oral delivery, the tablet uses specialized technology to survive stomach acid and be absorbed over several hours.
Available Wegovy pill milligrams
Wegovy comes in a fixed series of oral tablet strengths. Each higher strength is intended to be reached only after the prior level has been tolerated for a set period, usually four weeks. Below are the approved Wegovy pill milligrams and their clinical role, followed by a concise comparison table.
Evergreen dosing levels overview
- 0.25 mg: a very low starting dose to help your body adjust and to assess initial tolerance; not a therapeutic dose for weight loss.
- 0.5 mg: the first intended therapeutic dose for weight management, often maintained for four weeks.
- 1 mg: reached if 0.5 mg is tolerated, commonly maintained for at least four weeks.
- 1.7 mg: the highest approved maintenance strength for once-weekly oral use; introduced after completing the 1 mg titration period.
Wegovy pill milligrams at a glance
| Strength (mg) | Typical role | Titration timeline notes | Source type |
|---|---|---|---|
| 0.25 | Initial low dose for tolerance | Weeks 1–4 (minimum); not for weight loss | Prescribing information |
| 0.5 | First therapeutic weight management dose | Titrated up after ≥4 weeks if tolerated | Prescribing information |
| 1 | Intermediate maintenance dose | Titrated up after ≥4 weeks at 0.5 mg | Prescribing information |
| 1.7 | Maximum approved maintenance dose | Titrated up after ≥4 weeks at 1 mg | Prescribing information |
How dosing is titrated over time
Titration is the gradual upward adjustment of Wegovy pill milligrams to improve tolerability and allow your body to adapt. Starting at 0.25 mg, you stay at each level for at least four weeks (sometimes longer) before increasing. The usual sequence is 0.25 mg → 0.5 mg → 1 mg → 1.7 mg, but your clinician may adjust timing based on side effects and treatment goals. The slow climb helps reduce gastrointestinal symptoms and supports longer-term use. Dosing is always personalized; skipping levels or changing the schedule without medical guidance is not recommended.
Practical expectations at each level
- 0.25 mg: minimal impact on appetite or weight; focus on adjustment.
- 0.5 mg: many people begin to notice reduced hunger and earlier fullness; modest weight loss may start.
- 1 mg: stronger effect on appetite control and meal size; more consistent weight loss over time.
- 1.7 mg: the strongest approved dose, associated with greater average weight loss in clinical trials when tolerated.
Note that individual responses vary, and side effects can occur at any level. The goal is to use the lowest effective dose that you can tolerate long term rather than rushing to the highest strength.
How this compares with other semaglutide products
Wegovy is an oral form of semaglutide; another well-known semaglutide product, Ozempic and Rybelsus, are also available but in different formats and indications. Ozempic is a subcutaneous injection used for type 2 diabetes and weight management under medical supervision, while Rybelsus is an oral tablet approved for type 2 diabetes (not weight management). For adults using Wegovy for weight, the oral weekly tablet offers a needle-free option. However, not everyone is a candidate, and insurance coverage, medical history, and treatment goals influence which product is appropriate. Your clinician can help decide the best option based on your health profile and objectives.
Safety, side effects, and important considerations
Common side effects of Wegovy include nausea, vomiting, diarrhea, constipation, and stomach pain, especially during dose increases. Serious risks include thyroid C-cell tumors observed in animal studies; therefore, Wegovy is not recommended for people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. It also carries warnings about pancreatitis, gallbladder problems, kidney issues, and potential changes in heart rate. Before starting, discuss your full medical history, current medications, and mental health concerns with your clinician. Use a shared decision-making approach to weigh benefits and risks for your specific situation.
Lifestyle supports and long-term use
Wegovy is a tool, not a standalone solution. Healthy eating patterns, consistent physical activity, sleep, and behavioral strategies improve outcomes. Many people require ongoing treatment to maintain weight loss, and discontinuation can lead to weight regain. Work with your clinician to create a plan for how to taper or maintain, how to monitor progress, and when adjustments are needed. Regular follow-up visits support safety, motivation, and sustained change.